Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C

Epclusa is Gilead’s Third Sofosbuvir-Based Treatment to Receive a CHMP Positive Opinion for the Treatment of Chronic HCV Infection.

Published
27 May 2016
From
Gilled press relase
Gilead's $1000 hepatitis C pill gets patent in India

In what could be a major setback to access to treatment in high-burden countries, the Indian Patent Office on Monday granted a patent to Gilead Pharmasset on Sovaldi (sofosbuvir), its blockbuster drug for hepatitis C, for which the company charges $1,000 per pill in the US.

Published
10 May 2016
From
Times of India
Sky-high price of hepatitis C drug produces profits for lawmakers

While patients in Massachusetts await affordable doses of the blockbuster hepatitis C drug Sovaldi, Rep. Joseph Kennedy III has financially benefited from the success of the drug’s manufacturer, Gilead Sciences, according to public financial disclosures and campaign finance records.

Published
05 May 2016
From
Center for Responsive Politics
'Aggressive' pricing helps Merck steal hep C share with newcomer Zepatier

Merck & Co. has yet to report first-quarter earnings, so industry watchers still don’t know exactly how much market share the company’s new hep C combo treatment, Zepatier, has scored since winning approval in late January. But so far, comments from its competitors suggest it’s doing pretty well for itself.

Published
03 May 2016
From
Fierce Pharma
European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two doses of Descovy® (emtricitabine and tenofovir alafenamide 200/10 mg and 200/25 mg; F/TAF), a fixed-dose combination for the treatment of HIV-1 infection. Descovy is Gilead’s second TAF-based therapy to receive marketing authorization in the European Union.

Published
25 April 2016
From
Gilead press release
Gilead Statement on the Approval of PrEP in Peru

Gilead Sciences, Inc. is pleased to share that the Peru Ministry of Health has approved the use of once- daily oral Truvada® (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) as pre-exposure prophylaxis (PrEP), in combination with safer sex practices, to help reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk .

Published
14 April 2016
From
Gilead Sciences
Innovative new programme set to treat 10,000 patients co-infected with hepatitis C and HIV in Africa and Asia

The World Hepatitis Alliance welcomes the announcement of a new programme initiated by the Clinton Health Access Initiative, Inc. (CHAI) and AmeriCares that aims to treat 10,000 co-infected HIV and hepatitis C patients in Africa and Asia with new hepatitis C treatment Daklinza (daclatasvir).

Published
14 April 2016
From
World Hepatitis Alliance
PrEP Pricing Problems

A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them

Published
02 April 2016
From
TAG
Greed and the Necessity for Regulation

The story of U.S. drug pricing run amok isn’t just about corporate arrogance and avarice—it is also about government permissiveness and inaction

Published
02 April 2016
From
TAG
GSK eases IP rights for poorest countries, considers patent pooling for cancer

As the United Nations Secretary General’s High-Level Panel on Access to Medicines initiative continues its work, the GlaxoSmithKline company today announced steps to further help bring innovative medicines to poor countries.

Published
02 April 2016
From
Intellectual Property Watch
← First12345...86Next →

Filter by country